Q-omics provides the consensus-scored RPL29P29 profile across patient tissues and cancer cell-line models. RPL29P29 expression is associated with patient survival in 9 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, RPL29P29 is differentially expressed in 1, with the highest sampling consensus in KIRC. Additionally, RPL29P29 RNA expression shows 7,211 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight SKCM, KIRC, and TGCT as cancer lineages where RPL29P29 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPL29P29 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPL29P29 survival associations across molecular data types. RPL29P29 RNA expression shows survival associations in the most cancer types (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPL29P29 RNA expression–survival associations across cancer types. High RPL29P29 expression shows unfavorable associations in SKCM, COAD, READ and OV, but favorable associations in KIRC and TGCT. The SKCM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for RPL29P29 RNA expression.
This table summarizes RPL29P29 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for RPL29P29. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPL29P29 shows higher tumor expression in KIRC. The KIRC box plot shows higher RPL29P29 RNA expression in tumor versus normal tissue (log2 FC = +0.030, t-test p = .042).
This table shows molecular features associated with RPL29P29 in patient tissues and cancer cell lines. In patient samples, RPL29P29 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
